ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
 PMID: 34849981       2022       The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Lamivudine/dolutegravir maintenance DT showed similar efficacy to dolutegravir-based TT; however, past M184V/I may favour VF.
Abstract: Conversely, in the setting of pre-existing M184V/I, DT showed a trend to increased risk of VF (versus tenofovir-based TT, aHR = 137.50, 95% CI = 4.24-4464.06; versus abacavir-based TT, aHR = 33.88, 95% CI = 1.75-656.47).


  Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort.
 PMID: 34802406       2022       Current HIV research
Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.


  Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
 PMID: 34741609       2022       The Journal of antimicrobial chemotherapy
Result: All participants with K65R also had M184I/V.
Result: There was also a high prevalence of mutations among the 12 participants who were sampled less than 1 year after initiating first-line treatment: 6 (50%) had TAMs present at >=2% frequency; 10 (83%) had core NRTI mutations (of which all 10 had M184IV and 7 also had other core NRTI mutations); and 12 (100%) had NNRTI mutations.
Discussion: Notably, all participants in the present analysis who had the K65R mutation also had M184I/V.


  Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
 PMID: 34694877       2022       Antimicrobial agents and chemotherapy
Result: One participant (participant 1) had the integrase substitution R263R/K and NRTI resistance-associated substitutions K65R and M184I/V at baseline, despite no apparent prior INSTI treatment, but did not demonstrate in vitro dolutegravir phenotypic resistance.
Table: M184I/V
Discussion: Unusually, 1 participant had the highly conserved integrase substitutions R263R/K and M184I/V as mixtures at baseline but not at CVW.


  Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.
 PMID: 35495657       2022       Frontiers in microbiology
Abstract: The most prevalent TDR drug resistance mutations, in both LP and NLP, were K103N/S, T215rev, T215FY, M184I/V, M41I/L, M46I/L, and L90M.


  Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
 PMID: 35274144       2022       The Journal of antimicrobial chemotherapy
Abstract: PBMC DNA deep sequencing performed some months later revealed mutations M184I (14.29%) and M230I (6.25%) in the reverse transcriptase and G163R (9.77%) and S230N (98.8%) in the integrase.


  Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.
 PMID: 35293098       2022       HIV medicine
Abstract: The predominant DRMs for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs).


  Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
 PMID: 35302390       2022       AIDS research and human retroviruses
Abstract: M184V/I, K103N/S and Y181C were the most commonly occurring mutations, seen in 76%, 51% and 36% children.


  High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
 PMID: 35466963       2022       AIDS (London, England)
Abstract: Among adult participants, factors associated with preexisting M184 V/I included other resistance, Black race, Hispanic/Latinx ethnicity, lower baseline CD4 cell count, advanced HIV disease, longer duration of antiretroviral therapy, and greater number of prior third agents.
Abstract: At last on-treatment visit, 98% (179/182) with preexisting M184 V/I and 99% (2012/2034) of all B/F/TAF-treated participants had HIV-1 RNA <50 copies/mL, with no treatment-emergent resistance to B/F/TAF.
Abstract: CONCLUSIONS: M184 V/I was detected in 10% of virologically suppressed clinical trial participants at study baseline.


  Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
 PMID: 33635848       2021       AIDS (London, England)
Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.



Browser Board

 Co-occurred Entities




   Filtrator